

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 3**
March 2011



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

Department of Health and Human Services

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2011

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

Cumulative Supplement 3

March 2011

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

**CUMULATIVE SUPPLEMENT 3
March 2011**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 30th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 31st Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically

equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper

versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2010</u>	<u>MAR 2011</u>	<u>JUN 2011</u>	<u>SEPT 2011</u>	<u>DEC 2011</u>
DRUG PRODUCTS LISTED	13838	14029			
SINGLE SOURCE	2482	2477			
	(17.9%)	(17.7%)			
MULTISOURCE	11267	11463			
	(81.4%)	(81.7%)			
THERAPEUTICALLY EQUIVALENT	11107	11301			
	(80.3%)	(80.6%)			
NOT THERAPEUTICALLY EQUIVALENT	160	162			
	(1.2%)	(1.2%)			
EXCEPTIONS ¹	89	89			
	(0.6%)	(0.6%)			
NEW MOLECULAR ENTITIES APPROVED	8	6			
NUMBER OF APPLICANTS	752	768			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.

CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 31ST EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

1-1

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>D>	AA	CONCORD LABS NJ	325MG;50MG;40MG	A040864 001	Dec 01, 2008	Mar	CAHN
>D>	AA		500MG;50MG;40MG	A040883 001	Dec 23, 2008	Mar	CAHN
>A>	AA	MIRROR PHARMS	325MG;50MG;40MG	A040864 001	Dec 01, 2008	Mar	CAHN
>A>	AA		500MG;50MG;40MG	A040883 001	Dec 23, 2008	Mar	CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

AA		WRASER PHARMS LLC	356.4MG;30MG;16MG	A040688 001	Apr 03, 2007	Jan	CAHN
----	--	-------------------	-------------------	-------------	--------------	-----	------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		BOCA PHARMA	300MG;5MG	A090415 001	Jan 24, 2011	Feb	CTEC
AB			300MG;5MG	A090415 001	Jan 24, 2011	Jan	NEWA
AA			300MG;7.5MG	A090415 002	Jan 24, 2011	Feb	CTEC
AB			300MG;7.5MG	A090415 002	Jan 24, 2011	Jan	NEWA
AA			300MG;10MG	A090415 003	Jan 24, 2011	Feb	CTEC
AB			300MG;10MG	A090415 003	Jan 24, 2011	Jan	NEWA
>D>	AA	MIKART	300MG;5MG	A040658 001	Jan 19, 2006	Mar	CRLD
>A>	AA	+	300MG;5MG	A040658 001	Jan 19, 2006	Mar	CRLD
	AA		300MG;5MG	A040658 001	Jan 19, 2006	Feb	CTEC
	AA	+	300MG;7.5MG	A040556 002	Mar 24, 2006	Feb	CTEC
	AA	+	300MG;10MG	A040556 001	Jun 23, 2004	Feb	CTEC
		LORTAB					
AA		UCB INC	500MG;5MG	A087722 001	Jul 09, 1982	Jan	CAHN

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

>D>	AA	VINTAGE PHARMS	650MG;65MG	A040507 001	Jul 30, 2003	Mar	DISC
>A>		@	650MG;65MG	A040507 001	Jul 30, 2003	Mar	DISC

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET-N 100

@ XANODYNE PHARM 650MG;100MG

N017122 002 Jan DISC

DARVOCET-N 50

@ XANODYNE PHARM 325MG;50MG

N017122 001 Jan DISC

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

>D>	AB	CONCORD LABS NJ	650MG;100MG	A077821 001	Feb 11, 2008	Mar	CAHN
>D>		CORNERSTONE	325MG;100MG	A076743 001	May 07, 2004	Mar	DISC
>A>		@	325MG;100MG	A076743 001	May 07, 2004	Mar	DISC
>D>	AB		500MG;100MG	A076750 001	Jun 28, 2004	Mar	DISC
>A>		@	500MG;100MG	A076750 001	Jun 28, 2004	Mar	DISC
>A>	AB	MIRROR PHARMS	650MG;100MG	A077821 001	Feb 11, 2008	Mar	CAHN
>D>	AB	TEVA	650MG;100MG	A074119 001	Dec 19, 1994	Mar	DISC
>A>		@	650MG;100MG	A074119 001	Dec 19, 1994	Mar	DISC
>D>	AB	VINTAGE PHARMS	325MG;50MG	A074843 002	Feb 15, 2001	Mar	DISC
>A>		@	325MG;50MG	A074843 002	Feb 15, 2001	Mar	DISC

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

>D>	AB	VINTAGE PHARMS	650MG;100MG	A074843 001	Feb 12, 1997	Mar	DISC
>A>		@	650MG;100MG	A074843 001	Feb 12, 1997	Mar	DISC

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

AB	MYLAN	200MG	A074977 001	Apr 13, 1998	Feb	CAHN
----	-------	-------	-------------	--------------	-----	------

TABLET; ORAL

ACYCLOVIR

AB	MYLAN	400MG	A074976 001	Apr 13, 1998	Feb	CAHN
AB		800MG	A074976 002	Apr 13, 1998	Feb	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

@	HOSPIRA	EQ 50MG BASE/ML	A075065 001	Feb 25, 1999	Feb	DISC
---	---------	-----------------	-------------	--------------	-----	------

ALCLOMETASONE DIPROPIONATE

OINTMENT; TOPICAL

ACLOVATE

>D>	AB	+	GLAXOSMITHKLINE	0.05%	N018702 001	Dec 14, 1982	Mar	CAHN
>A>	AB	+	NYCOMED US	0.05%	N018702 001	Dec 14, 1982	Mar	CAHN

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

AB	MYLAN	EQ 35MG BASE	A078638 001	Aug 04, 2008	Feb	CAHN	
AB		EQ 70MG BASE	A078638 002	Aug 04, 2008	Feb	CAHN	
>D>	AB	SANDOZ	EQ 5MG BASE	A075871 001	Apr 22, 2009	Mar	DISC
>A>		@	EQ 5MG BASE	A075871 001	Apr 22, 2009	Mar	DISC
>D>	AB		EQ 10MG BASE	A075871 002	Apr 22, 2009	Mar	DISC
>A>		@	EQ 10MG BASE	A075871 002	Apr 22, 2009	Mar	DISC
>D>	AB		EQ 35MG BASE	A075871 004	Apr 22, 2009	Mar	DISC
>A>		@	EQ 35MG BASE	A075871 004	Apr 22, 2009	Mar	DISC
>D>	AB		EQ 40MG BASE	A075871 003	Apr 22, 2009	Mar	DISC
>A>		@	EQ 40MG BASE	A075871 003	Apr 22, 2009	Mar	DISC
>D>	AB		EQ 70MG BASE	A075871 005	Apr 22, 2009	Mar	DISC
>A>		@	EQ 70MG BASE	A075871 005	Apr 22, 2009	Mar	DISC

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB	IPCA LABS LTD	100MG	A090637 001	Mar 16, 2011	Feb	NEWA
AB		300MG	A090637 002	Mar 16, 2011	Feb	NEWA

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

>A>	AB	HIKMA PHARMS	EQ 2.5MG BASE	A077771 001	Apr 12, 2011	Mar	NEWA
>A>	AB		EQ 5MG BASE	A077771 002	Apr 12, 2011	Mar	NEWA
>A>	AB		EQ 10MG BASE	A077771 003	Apr 12, 2011	Mar	NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

LOTREL

AB	NOVARTIS	EQ 5MG BASE;40MG	N020364 007	Apr 11, 2006	Jan	CFTG
AB	+	EQ 10MG BASE;40MG	N020364 006	Apr 11, 2006	Jan	CFTG

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB	AM ANTIBIOTICS	250MG	A062058 001		Feb	CDFR
AB		500MG	A062058 002		Feb	CDFR

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	SANTOS BIOTECH	1MG	A078944 001	Jun 28, 2010	Feb	CAHN
----	----------------	-----	-------------	--------------	-----	------

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

>D>	AB	CONCORD LABS NJ	325MG;200MG	A040832 001	Jan 07, 2010	Mar	CAHN
>A>	AB	MIRROR PHARMS	325MG;200MG	A040832 001	Jan 07, 2010	Mar	CAHN
	AB	PROSAM LABS	325MG;200MG	A040252 001	Dec 10, 1997	Feb	CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

>D>	AB	CONCORD LABS NJ	325MG;200MG;16MG	A040860 001	Jan 07, 2010	Mar	CAHN
>A>	AB	MIRROR PHARMS	325MG;200MG;16MG	A040860 001	Jan 07, 2010	Mar	CAHN
	AB	PROSAM LABS	325MG;200MG;16MG	A040283 001	Dec 29, 1998	Feb	CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA	COASTAL PHARMS	325MG;4.8355MG	A091670 001	Mar 16, 2011	Feb	NEWA	
>A>	AA	WATSON LABS	325MG;4.8355MG	A090084 001	Mar 22, 2011	Mar	NEWA
		PERCODAN					
AA	+	ENDO PHARMS	325MG;4.8355MG	N007337 007	Aug 05, 2005	Feb	CFTG

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	MYLAN	25MG	A074126 003	Aug 26, 1998	Feb	CAHN
AB		50MG	A074126 001	Mar 23, 1994	Feb	CAHN
AB		100MG	A074126 002	Mar 23, 1994	Feb	CAHN

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB	GLENMARK GENERICS	250MG;100MG	A091211 001	Jan 12, 2011	Jan	NEWA	
		MALARONE					
AB	+	GLAXOSMITHKLINE	250MG;100MG	N021078 001	Jul 14, 2000	Jan	CFTG

AZILSARTAN MEDOXOMIL

TABLET; ORAL

EDARBI

TAKEDA PHARMS	40MG	N200796 001	Feb 25, 2011	Feb	NEWA
+	80MG	N200796 002	Feb 25, 2011	Feb	NEWA

AZTREONAM

INJECTABLE; INJECTION

AZTREONAM

>A>	AP	BEDFORD	1GM/VIAL	A065286 001	Mar 23, 2011	Mar	NEWA
>A>	AP		2GM/VIAL	A065286 002	Mar 23, 2011	Mar	NEWA

BACITRACIN

OINTMENT; OPHTHALMIC

BACITRACIN

+	FERA PHARMS	500 UNITS/GM	A061212 001		Feb	CAHN
+	NYCOMED US	500 UNITS/GM	A061212 001		Jan	CAHN

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT	FERA PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764 002		Feb	CAHN
AT	NYCOMED US	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764 002		Jan	CAHN

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	FERA PHARMS	500 UNITS/GM;10,000 UNITS/GM	A065022 001	Feb 27, 2002	Feb	CAHN
AT	NYCOMED US	500 UNITS/GM;10,000 UNITS/GM	A065022 001	Feb 27, 2002	Jan	CAHN

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

+	FERA PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166 002		Feb	CAHN
+	NYCOMED US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166 002		Jan	CAHN

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

AP	CNS THERAPS INC	0.05MG/ML	N022462 001	Nov 19, 2010	Feb	CTEC
AP		0.5MG/ML	N022462 002	Nov 19, 2010	Feb	CTEC
AP		2MG/ML	N022462 003	Nov 19, 2010	Feb	CTEC

LIORESAL

AP	+	MEDTRONIC	0.05MG/ML	N020075 003	Nov 07, 1996	Feb	CTEC
AP	+		0.5MG/ML	N020075 001	Jun 17, 1992	Feb	CTEC
AP	+		2MG/ML	N020075 002	Jun 17, 1992	Feb	CTEC

TABLET; ORAL

BACLOFEN

AB	PROSAM LABS	10MG	A077089 001	Oct 31, 2007	Feb	CAHN
AB		20MG	A077088 001	Oct 31, 2007	Feb	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	5MG;6.25MG	A076612 001	Feb 11, 2004	Feb	CAHN
AB		10MG;12.5MG	A076612 002	Feb 11, 2004	Feb	CAHN
AB		20MG;12.5MG	A076612 003	Feb 11, 2004	Feb	CAHN
AB		20MG;25MG	A076612 004	Feb 11, 2004	Feb	CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP	LUITPOLD	1MG/ML	A091152 001	Mar 29, 2010	Feb	CAHN
----	----------	--------	-------------	--------------	-----	------

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

>A>	AB	ROXANE	50MG	A078285 001	Mar 24, 2011	Mar	NEWA
-----	----	--------	------	-------------	--------------	-----	------

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMDAY

>D>		ISTA PHARMS	0.09%	N021664 002	Oct 16, 2010	Mar	CRLD
>A>	+	ISTA PHARMS INC	0.09%	N021664 002	Oct 16, 2010	Mar	CRLD
>D>		XIBROM					
>D>	+	ISTA PHARMS	0.09%	N021664 001	Mar 24, 2005	Mar	DISC
>A>	@	ISTA PHARMS INC	0.09%	N021664 001	Mar 24, 2005	Mar	DISC

CALCIPOTRIENE

SOLUTION; TOPICAL

CALCIPOTRIENE

>A>	AT	G AND W LABS INC	0.005%	A078468 001	Mar 24, 2011	Mar	NEWA
-----	----	------------------	--------	-------------	--------------	-----	------

CALCIUM ACETATE

TABLET; ORAL

CALCIUM ACETATE

>A>	AB	PADDOCK LABS	EQ 160MG CALCIUM	A091561 001	Apr 13, 2011	Mar	NEWA
		ELIPHOS					
>D>	+	CYPRESS PHARM	EQ 169MG CALCIUM	A078502 001	Nov 25, 2008	Mar	CTEC
>A>	AB	+	EQ 169MG CALCIUM	A078502 001	Nov 25, 2008	Mar	CTEC

CARBAMAZEPINE

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

	@	JUBILANT CADISTA	100MG	A071940 001	Feb 01, 1988	Jan	CAHN
--	---	------------------	-------	-------------	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET; ORAL

SINEMET

AB	MERCK SHARP DOHME	10MG;100MG	N017555 001		Jan	CAHN
AB		25MG;100MG	N017555 003		Jan	CAHN
AB	+	25MG;250MG	N017555 002		Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL

SINEMET CR

AB	MERCK SHARP DOHME	25MG;100MG	N019856 002	Dec 24, 1992	Jan	CAHN
AB	+	50MG;200MG	N019856 001	May 30, 1991	Jan	CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

>D>	AA	CONCORD LABS NJ	350MG	A040823	001	Oct 22, 2008	Mar	CAHN
>A>	AA	MIRROR PHARMS	350MG	A040823	001	Oct 22, 2008	Mar	CAHN
	AA	PROSAM LABS	350MG	A040188	001	Mar 07, 1997	Feb	CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP		HOSPIRA INC	EQ 500MG BASE/VIAL	A065226	001	Apr 21, 2005	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065226	002	Apr 21, 2005	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065244	001	Aug 12, 2005	Jan	CAHN
AP			EQ 10GM BASE/VIAL	A065247	001	Aug 12, 2005	Jan	CAHN

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

AP		HOSPIRA INC	EQ 500MG BASE/VIAL	A065369	001	Jun 18, 2007	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065369	002	Jun 18, 2007	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065369	003	Jun 18, 2007	Jan	CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

AP		HOSPIRA INC	EQ 500MG BASE/VIAL	A065290	001	Aug 11, 2006	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065290	002	Aug 11, 2006	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065293	001	Aug 10, 2006	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065290	003	Aug 11, 2006	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065293	002	Aug 10, 2006	Jan	CAHN
AP			EQ 10GM BASE/VIAL	A065292	001	Aug 10, 2006	Jan	CAHN

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP		HOSPIRA INC	EQ 1GM BASE/VIAL	A065313	001	Jan 23, 2006	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065313	002	Jan 23, 2006	Jan	CAHN
AP			EQ 10GM BASE/VIAL	A065312	001	Feb 13, 2006	Jan	CAHN

CEFPODOXIME PROXETIL

TABLET; ORAL

CEFPODOXIME PROXETIL

AB	+	SANDOZ	EQ 200MG BASE	A065462	002	May 28, 2008	Jan	CRLD
		VANTIN						
		@ PHARMACIA AND UPJOHN	EQ 100MG BASE	N050674	001	Aug 07, 1992	Jan	DISC
		@	EQ 200MG BASE	N050674	002	Aug 07, 1992	Jan	DISC

CEFTRIAZONE SODIUM

INJECTABLE; IM-IV

CEFTRIAZONE

AP		HOSPIRA INC	EQ 250MG BASE/VIAL	A065230	001	Aug 02, 2005	Jan	CAHN
AP			EQ 500MG BASE/VIAL	A065230	002	Aug 02, 2005	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065230	003	Aug 02, 2005	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065230	004	Aug 02, 2005	Jan	CAHN

INJECTABLE; INJECTIONCEFTRIAXONE

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065231 001	Aug 02, 2005	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065231 002	Aug 02, 2005	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065232 001	Aug 02, 2005	Jan	CAHN
AP	+ SANDOZ	EQ 10GM BASE/VIAL	A065168 001	May 17, 2005	Jan	CRLD

CEFUROXIME SODIUMINJECTABLE; IM-IVCEFUROXIME SODIUM

>D>	AP	HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	A065048 001	Jan 09, 2004	Mar	CTEC
>A>	AB		EQ 750MG BASE/VIAL	A065048 001	Jan 09, 2004	Mar	CTEC
	AP	HOSPIRA INC	EQ 750MG BASE/VIAL	A065483 001	Oct 15, 2008	Jan	CAHN

INJECTABLE; INJECTIONCEFUROXIME SODIUM

AP	HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065483 002	Oct 15, 2008	Jan	CAHN
AP		EQ 1.5GM BASE/VIAL	A065503 001	Oct 15, 2008	Jan	CAHN
AP		EQ 7.5GM BASE/VIAL	A065484 001	Oct 15, 2008	Jan	CAHN

CEPHALEXINFOR SUSPENSION; ORALCEPHALEXIN

		@ ACS DOBFAR	EQ 100MG BASE/ML	A062117 001		Jan	CAHN
AB			EQ 125MG BASE/5ML	A062117 002		Jan	CAHN
AB	+		EQ 250MG BASE/5ML	A062117 003		Jan	CAHN

CHLORHEXIDINE GLUCONATESOLUTION; DENTALCHLORHEXIDINE GLUCONATE

AT	LYNE	0.12%	A074291 001	Dec 28, 1995	Feb	CAHN
----	------	-------	-------------	--------------	-----	------

CHLOROQUINE PHOSPHATETABLET; ORALCHLOROQUINE PHOSPHATE

AA	NATCO PHARMA LTD	EQ 150MG BASE	A091621 001	Jan 21, 2011	Jan	NEWA
AA		EQ 300MG BASE	A090612 001	Jan 21, 2011	Jan	NEWA

CHOLESTYRAMINEPOWDER; ORALQUESTRAN LIGHT

>D>	AB	BRISTOL MYERS	EQ 4GM RESIN/PACKET	N019669 001	Dec 05, 1988	Mar	CRLD
>A>	AB	+	EQ 4GM RESIN/PACKET	N019669 001	Dec 05, 1988	Mar	CRLD

CICLOPIROXSHAMPOO; TOPICALCICLOPIROX

AT	TARO	1%	A090269 001	Feb 23, 2011	Feb	NEWA
----	------	----	-------------	--------------	-----	------

CLINDAMYCIN PHOSPHATEGEL; TOPICALCLINDAGEL

>D>	BT	GALDERMA LABS LP	EQ 1% BASE	N050782 001	Nov 27, 2000	Mar	CRLD
>A>	BT	+	EQ 1% BASE	N050782 001	Nov 27, 2000	Mar	CRLD

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

AP	WEST WARD	1MG/10ML (0.1MG/ML)	A200300 001	Jan 26, 2011	Jan	NEWA
AP		5MG/10ML (0.5MG/ML)	A200300 002	Jan 26, 2011	Jan	NEWA

COLCHICINE; PROBENECID

TABLET; ORAL

PROBENECID AND COLCHICINE

>D>	AB	CONCORD LABS NJ	0.5MG;500MG	A040618 001	May 13, 2008	Mar	CAHN
>A>	AB	MIRROR PHARMS	0.5MG;500MG	A040618 001	May 13, 2008	Mar	CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	JUBILANT CADISTA	5MG	A077563 001	Apr 19, 2006	Jan	CAHN
AB		10MG	A077563 002	Apr 19, 2006	Jan	CAHN
AB	KVK TECH	5MG	A078048 001	Feb 28, 2011	Feb	NEWA
AB		10MG	A078048 002	Feb 28, 2011	Feb	NEWA
AB	PROSAM LABS	5MG	A077291 001	Feb 03, 2006	Feb	CAHN
AB		10MG	A077209 001	Oct 04, 2005	Feb	CAHN

DESLOMATADINE

TABLET; ORAL

DESLOMATADINE

AB	DR REDDYS LABS LTD	5MG	A078365 001	Mar 08, 2011	Feb	NEWA
----	--------------------	-----	-------------	--------------	-----	------

DESGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

EMOQUETTE

AB	VINTAGE	0.15MG;0.03MG	A076675 001	Feb 25, 2011	Feb	NEWA
----	---------	---------------	-------------	--------------	-----	------

DESOXIMETASONE

GEL; TOPICAL

DESOXIMETASONE

AB	VERSAPHARM	0.05%	A090727 001	Mar 10, 2011	Feb	NEWA
----	------------	-------	-------------	--------------	-----	------

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT	FERA PHARMS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938 001	Jul 31, 1989	Feb	CAHN
AT	NYCOMED US	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938 001	Jul 31, 1989	Jan	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA	AMNEAL PHARMS	15MG/5ML;6.25MG/5ML	A090575 001	Feb 08, 2011	Jan	NEWA
----	---------------	---------------------	-------------	--------------	-----	------

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

AB	PROSAM LABS	25MG	A040542 001	Apr 21, 2006	Feb	CAHN
AB		50MG	A040542 002	Apr 21, 2006	Feb	CAHN

TABLET; ORAL

DIPYRIDAMOLE

AB	PROSAM LABS	75MG	A040542 003	Apr 21, 2006	Feb	CAHN
----	-------------	------	-------------	--------------	-----	------

DISULFIRAM

TABLET; ORAL

ANTABUSE

>D>	ODYSSEY PHARMS	250MG	A088482 001	Dec 08, 1983	Mar	CTEC
>A>	AB	250MG	A088482 001	Dec 08, 1983	Mar	CTEC
>D>	+	500MG	A088483 001	Dec 08, 1983	Mar	CTEC
>A>	AB +	500MG	A088483 001	Dec 08, 1983	Mar	CTEC

DISULFIRAM

>A>	AB	SIGMAPHARM LABS LLC	250MG	A091619 001	Mar 28, 2011	Mar	NEWA
>A>	AB		500MG	A091619 002	Mar 28, 2011	Mar	NEWA

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DIVALPROEX SODIUM

>A>	AB	MYLAN	EQ 125MG VALPROIC ACID	A090407 001	Mar 28, 2011	Mar	NEWA
-----	----	-------	------------------------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

>A>	AB	UNICHEM LABS LTD	EQ 125MG VALPROIC ACID	A079163 001	Apr 05, 2011	Mar	NEWA
>A>	AB		EQ 250MG VALPROIC ACID	A079163 002	Apr 05, 2011	Mar	NEWA
>A>	AB		EQ 500MG VALPROIC ACID	A079163 003	Apr 05, 2011	Mar	NEWA
	AB	WATSON LABS FLORIDA	EQ 500MG BASE VALPROIC ACID	A079080 001	Feb 25, 2011	Feb	NEWA

DOCETAXEL

INJECTABLE; INJECTION

>A>	DOCETAXEL						
>A>	+	HOSPIRA INC	20MG/2ML (10MG/ML)	N022234 001	Mar 08, 2011	Mar	NEWA
>A>	+		80MG/8ML (10MG/ML)	N022234 002	Mar 08, 2011	Mar	NEWA
>A>	+		160MG/16ML (10MG/ML)	N022234 003	Mar 08, 2011	Mar	NEWA
	TAXOTERE						
>D>	+	SANOFI AVENTIS US	EQ 40MG BASE/ML	N020449 001	May 14, 1996	Mar	DISC
>A>	@		40MG/ML	N020449 001	May 14, 1996	Mar	DISC

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	IMPAX LABS INC	EQ 150MG BASE	A200065 001	Feb 17, 2011	Jan	NEWA	
AB	MYLAN	40MG	A090855 001	Jul 01, 2010	Jan	CDFR	
AB	+	PAR PHARM	EQ 150MG BASE	A065055 003	Jul 15, 2005	Feb	CTEC
AB	+		EQ 150MG BASE	A065055 003	Jul 15, 2005	Jan	CTEC

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

>A>	LORYNA						
>A>	AB	SANDOZ	3MG;0.02MG	A079221 001	Mar 28, 2011	Mar	NEWA
>A>	SYEDA						
>A>	AB	SANDOZ	3MG;0.03MG	A090114 001	Mar 28, 2011	Mar	NEWA

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

LOVENOX

	SANOFI AVENTIS US	300MG/3ML (100MG/ML)	N020164 009	Jan 23, 2003	Feb	CDFR
--	-------------------	----------------------	-------------	--------------	-----	------

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ELESTAT

AT	+	ALLERGAN	0.05%	N021565 001	Oct 16, 2003	Feb	CFTG
----	---	----------	-------	-------------	--------------	-----	------

EPINASTINE HYDROCHLORIDE

AT		CYPRESS PHARM	0.05%	A090870 001	Mar 14, 2011	Feb	NEWA
----	--	---------------	-------	-------------	--------------	-----	------

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYTHROMYCIN

AB		ARBOR PHARMS INC	250MG	A062746 001	Dec 22, 1986	Jan	CAHN
----	--	------------------	-------	-------------	--------------	-----	------

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT	+	FERA PHARMS	0.5%	A062447 001	Sep 26, 1983	Feb	CAHN
----	---	-------------	------	-------------	--------------	-----	------

AT	+	NYCOMED US	0.5%	A062447 001	Sep 26, 1983	Jan	CAHN
----	---	------------	------	-------------	--------------	-----	------

SOLUTION; TOPICAL

ERYDERM

	@	ARBOR PHARMS INC	2%	A062290 001		Jan	CAHN
--	---	------------------	----	-------------	--	-----	------

TABLET; ORAL

ERYTHROMYCIN

		ARBOR PHARMS INC	250MG	A061621 001		Jan	CAHN
--	--	------------------	-------	-------------	--	-----	------

+ 500MG

A061621 002		Jan	CAHN
-------------	--	-----	------

TABLET, COATED PARTICLES; ORAL

PCE

		ARBOR PHARMS INC	333MG	N050611 001	Sep 09, 1986	Jan	CAHN
--	--	------------------	-------	-------------	--------------	-----	------

+ 500MG

N050611 002	Aug 22, 1990	Jan	CAHN
-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

E-MYCIN

	@	ARBOR PHARMS INC	250MG	A060272 001		Jan	CAHN
--	---	------------------	-------	-------------	--	-----	------

	@		333MG	A060272 002		Jan	CAHN
--	---	--	-------	-------------	--	-----	------

ERY-TAB

+		ARBOR PHARMS INC	250MG	A062298 001		Jan	CAHN
---	--	------------------	-------	-------------	--	-----	------

+			333MG	A062298 003	Mar 29, 1982	Jan	CAHN
---	--	--	-------	-------------	--------------	-----	------

+			500MG	A062298 002		Jan	CAHN
---	--	--	-------	-------------	--	-----	------

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

E.E.S.

AB		ARBOR PHARMS INC	EQ 200MG BASE/5ML	N050207 001		Jan	CAHN
----	--	------------------	-------------------	-------------	--	-----	------

ERYPED

AB		ARBOR PHARMS INC	EQ 200MG BASE/5ML	N050207 003	Mar 30, 1987	Jan	CAHN
----	--	------------------	-------------------	-------------	--------------	-----	------

+			EQ 400MG BASE/5ML	N050207 002		Jan	CAHN
---	--	--	-------------------	-------------	--	-----	------

SUSPENSION; ORAL

E.E.S. 200

AB		ARBOR PHARMS INC	EQ 200MG BASE/5ML	A061639 001		Jan	CAHN
----	--	------------------	-------------------	-------------	--	-----	------

E.E.S. 400

AB	+	ARBOR PHARMS INC	EQ 400MG BASE/5ML	A061639 002		Jan	CAHN
----	---	------------------	-------------------	-------------	--	-----	------

PEDIAMYCIN

AB		ARBOR PHARMS INC	EQ 200MG BASE/5ML	A062304 001		Jan	CAHN
----	--	------------------	-------------------	-------------	--	-----	------

PEDIAMYCIN 400

AB		ARBOR PHARMS INC	EQ 400MG BASE/5ML	A062304 002		Jan	CAHN
----	--	------------------	-------------------	-------------	--	-----	------

TABLET; ORAL

E.E.S. 400

	@	ARBOR PHARMS INC	EQ 400MG BASE	A061905 001		Jan	CAHN
--	---	------------------	---------------	-------------	--	-----	------

BX	+		EQ 400MG BASE	A061905 002	Aug 12, 1982	Jan	CAHN
----	---	--	---------------	-------------	--------------	-----	------

TABLET; ORAL

ERYTHROMYCIN ETHYLSUCCINATE

BX	+	ARBOR PHARMS INC	EQ 400MG BASE	A061904 001		Jan	CAHN
----	---	------------------	---------------	-------------	--	-----	------

TABLET, CHEWABLE; ORAL

E.E.S.

	@	ARBOR PHARMS INC	EQ 200MG BASE	N050297 002		Jan	CAHN
--	---	------------------	---------------	-------------	--	-----	------

ERYPED

	@	ARBOR PHARMS INC	EQ 200MG BASE	N050297 003	Jul 05, 1988	Jan	CAHN
--	---	------------------	---------------	-------------	--------------	-----	------

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROCIN STEARATE

	@	ARBOR PHARMS INC	EQ 125MG BASE	A060359 002		Jan	CAHN
--	---	------------------	---------------	-------------	--	-----	------

			EQ 250MG BASE	A060359 001		Jan	CAHN
--	--	--	---------------	-------------	--	-----	------

+			EQ 500MG BASE	A060359 003		Jan	CAHN
---	--	--	---------------	-------------	--	-----	------

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ACTIVELLA

>D>		NOVO NORDISK INC	0.5MG;0.1MG	N020907 002	Dec 28, 2006	Mar	CTEC
-----	--	------------------	-------------	-------------	--------------	-----	------

>A>	AB		0.5MG;0.1MG	N020907 002	Dec 28, 2006	Mar	CTEC
-----	----	--	-------------	-------------	--------------	-----	------

ESTRADIOL AND NORETHINDRONE ACETATE

>A>	AB	BRECKENRIDGE PHARM	0.5MG;0.1MG	A078324 002	Apr 04, 2011	Mar	NEWA
-----	----	--------------------	-------------	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

BRIELLYN

>A>	AB	GLENMARK GENERICS	0.035MG;0.4MG	A090538 001	Mar 22, 2011	Mar	NEWA
-----	----	-------------------	---------------	-------------	--------------	-----	------

TABLET, CHEWABLE; ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

+		WARNER CHILCOTT	0.025MG;0.8MG	N022573 001	Dec 22, 2010	Jan	CRLD
---	--	-----------------	---------------	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-28

GILDESS FE 1.5/30

AB		VINTAGE	0.03MG;1.5MG	A077075 001	Apr 28, 2005	Jan	CTNA
----	--	---------	--------------	-------------	--------------	-----	------

GILDESS FE 1/20

AB		VINTAGE	0.02MG;1MG	A077077 001	May 20, 2005	Jan	CTNA
----	--	---------	------------	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

AB		WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A090479 001	Mar 09, 2011	Feb	NEWA
----	--	-------------	---	-------------	--------------	-----	------

ETODOLAC

CAPSULE; ORAL

ETODOLAC

	@	MYLAN	200MG	A075071 001	Sep 30, 1998	Feb	CAHN
--	---	-------	-------	-------------	--------------	-----	------

	@		300MG	A075071 002	Sep 30, 1998	Feb	CAHN
--	---	--	-------	-------------	--------------	-----	------

TABLET; ORAL

ETODOLAC

	@	MYLAN	400MG	A075012 001	Sep 30, 1998	Feb	CAHN
--	---	-------	-------	-------------	--------------	-----	------

	@		500MG	A075012 002	Sep 30, 1998	Feb	CAHN
--	---	--	-------	-------------	--------------	-----	------

ETRAVIRINE

TABLET; ORAL

INTELENCE

TIBOTEC

100MG

N022187 001 Jan 18, 2008 Jan CRLD

+

200MG

N022187 002 Dec 22, 2010 Jan NEWA

EXEMESTANE

TABLET; ORAL

AROMASIN

>D> + PHARMACIA AND UPJOHN 25MG

N020753 001 Oct 21, 1999 Mar CFTG

>A> AB + 25MG

N020753 001 Oct 21, 1999 Mar CFTG

>A> EXEMESTANE

>A> AB ROXANE 25MG

A077431 001 Apr 01, 2011 Mar NEWA

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

>A> AB AUROBINDO PHARMA LTD 125MG

A091114 001 Mar 21, 2011 Mar NEWA

>A> AB 250MG

A091114 002 Mar 21, 2011 Mar NEWA

>A> AB 500MG

A091114 003 Mar 21, 2011 Mar NEWA

>A> AB MYLAN 125MG

A201333 001 Mar 24, 2011 Mar NEWA

>A> AB 250MG

A201333 002 Mar 24, 2011 Mar NEWA

>A> AB 500MG

A201333 003 Mar 24, 2011 Mar NEWA

>A> AB ROXANE 125MG

A090128 001 Mar 21, 2011 Mar NEWA

>A> AB 250MG

A090128 002 Mar 21, 2011 Mar NEWA

>A> AB 500MG

A090128 003 Mar 21, 2011 Mar NEWA

>A> AB WATSON LABS 125MG

A078278 001 Mar 21, 2011 Mar NEWA

>A> AB 250MG

A078278 002 Mar 21, 2011 Mar NEWA

>A> AB 500MG

A078278 003 Mar 21, 2011 Mar NEWA

FAMOTIDINE

INJECTABLE; INJECTION

PEPCID

@ MERCK

10MG/ML

N019510 001 Nov 04, 1986 Jan DISC

PEPCID PRESERVATIVE FREE

@ MERCK

10MG/ML

N019510 004 Nov 04, 1986 Jan DISC

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

@ MERCK

0.4MG/ML

N020249 001 Feb 18, 1994 Jan DISC

TABLET; ORAL

FAMOTIDINE

AB MYLAN 20MG

A075457 001 Apr 18, 2001 Feb CAHN

AB 40MG

A075457 002 Apr 18, 2001 Feb CAHN

FENOFIBRATE

TABLET; ORAL

FENOGLIDE

SHORE THERAP

40MG

N022118 001 Aug 10, 2007 Feb CAHN

+

120MG

N022118 002 Aug 10, 2007 Feb CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

AB MALLINCKRODT INC 100MCG/HR

A077154 004 Feb 09, 2011 Jan NEWA

FENTANYL-25

AB MALLINCKRODT INC 25MCG/HR

A077154 001 Feb 09, 2011 Jan NEWA

FILM, EXTENDED RELEASE; TRANSDERMALFENTANYL-50

AB	MALLINCKRODT INC	50MCG/HR	A077154 002	Feb 09, 2011	Jan	NEWA
----	------------------	----------	-------------	--------------	-----	------

FENTANYL-75

AB	MALLINCKRODT INC	75MCG/HR	A077154 003	Feb 09, 2011	Jan	NEWA
----	------------------	----------	-------------	--------------	-----	------

FENTANYL CITRATETABLET; SUBLINGUALABSTRAL

PROSTRAKAN INC

EQ 0.1MG BASE

N022510 001 Jan 07, 2011 Jan NEWA

EQ 0.2MG BASE

N022510 002 Jan 07, 2011 Jan NEWA

EQ 0.3MG BASE

N022510 003 Jan 07, 2011 Jan NEWA

+

EQ 0.4MG BASE

N022510 004 Jan 07, 2011 Jan NEWA

EQ 0.6MG BASE

N022510 005 Jan 07, 2011 Jan NEWA

EQ 0.8MG BASE

N022510 006 Jan 07, 2011 Jan NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORALFEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS LTD 180MG;240MG

A079043 001 Mar 17, 2010 Jan CTEC

FLUCONAZOLETABLET; ORALFLUCONAZOLE

AB AMNEAL PHARM

50MG

A078423 001 Mar 07, 2011 Feb NEWA

AB 100MG

A078423 002 Mar 07, 2011 Feb NEWA

AB 150MG

A078423 003 Mar 07, 2011 Feb NEWA

AB 200MG

A078423 004 Mar 07, 2011 Feb NEWA

AB MYLAN 50MG

A076042 001 Jul 29, 2004 Feb CAHN

AB 100MG

A076042 002 Jul 29, 2004 Feb CAHN

AB 150MG

A076042 003 Jul 29, 2004 Feb CAHN

AB 200MG

A076042 004 Jul 29, 2004 Feb CAHN

FLUDARABINE PHOSPHATETABLET; ORALOFORTA

@ SANOFI AVENTIS US

10MG

N022273 001 Dec 18, 2008 Jan DISC

FLUDEOXYGLUCOSE F-18INJECTABLE; INTRAVENOUSFLUDEOXYGLUCOSE F18

AP + FEINSTEIN 20-200mCi/ML

N021870 001 Aug 19, 2005 Feb CTEC

AP PETNET 20-200mCi/ML

A079086 001 Feb 25, 2011 Feb NEWA

FLUOROURACILINJECTABLE; INJECTIONFLUOROURACIL

>D> AP + VALEANT 500MG/10ML (50MG/ML)

N012209 001 Mar DISC

>A> + @ 500MG/10ML (50MG/ML)

N012209 001 Mar DISC

FLUTAMIDECAPSULE; ORALFLUTAMIDE

AB MYLAN 125MG

A076224 001 May 09, 2003 Feb CAHN

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

@ MYLAN

50MG

A075950 001 Oct 15, 2001 Feb CAHN

@

100MG

A075950 002 Oct 15, 2001 Feb CAHN

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA JUBILANT CADISTA

1MG

A040514 001 Jun 14, 2005 Jan CAHN

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

>A> AB AUROBINDO PHARMA LTD 10MG

A091163 001 Mar 30, 2011 Mar NEWA

>A> AB 20MG

A091163 002 Mar 30, 2011 Mar NEWA

>A> AB 40MG

A091163 003 Mar 30, 2011 Mar NEWA

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB MATRIX LABS LTD 100MG

A090158 001 Feb 14, 2011 Jan NEWA

AB 300MG

A090158 002 Feb 14, 2011 Jan NEWA

AB 400MG

A090158 003 Feb 14, 2011 Jan NEWA

SOLUTION; ORAL

GABAPENTIN

AA HI TECH PHARMA 250MG/5ML

A078974 001 Feb 18, 2011 Feb NEWA

NEURONTIN

AA + PARKE DAVIS 250MG/5ML

N021129 001 Mar 02, 2000 Feb CFTG

TABLET; ORAL

GABAPENTIN

AB ZYDUS PHARMS USA INC 600MG

A078926 001 Feb 11, 2011 Jan NEWA

AB 800MG

A078926 002 Feb 11, 2011 Jan NEWA

GRALISE

BX + ABBOTT PRODS 300MG

N022544 001 Jan 28, 2011 Jan NEWA

BX + 600MG

N022544 002 Jan 28, 2011 Jan NEWA

>A> GADOBUTROL

>A> SOLUTION; INTRAVENOUS

>A> GADAVIST

>A> + BAYER HLTHCARE 4.5354GM/7.5ML (604.72MG/ML)

N201277 001 Mar 14, 2011 Mar NEWA

>A> + 6.0472GM/10ML (604.72MG/ML)

N201277 002 Mar 14, 2011 Mar NEWA

>A> + 9.0708GM/15ML (604.72MG/ML)

N201277 003 Mar 14, 2011 Mar NEWA

>A> + 18.1416GM/30ML (604.72MG/ML)

N201277 004 Mar 14, 2011 Mar NEWA

>A> + 39.3068GM/65ML (604.72MG/ML)

N201277 005 Mar 14, 2011 Mar NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

AB MYLAN EQ 8MG BASE

A090900 001 Jan 24, 2011 Jan NEWA

AB EQ 16MG BASE

A090900 002 Jan 24, 2011 Jan NEWA

AB EQ 24MG BASE

A090900 003 Jan 24, 2011 Jan NEWA

AB SUN PHARMA GLOBAL EQ 8MG BASE

A090178 001 Feb 02, 2011 Jan NEWA

AB EQ 16MG BASE

A090178 002 Feb 02, 2011 Jan NEWA

AB EQ 24MG BASE

A090178 003 Feb 02, 2011 Jan NEWA

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

>A>	AB	AUROBINDO PHARMA LTD	EQ 4MG BASE	A090957	001	Mar 29, 2011	Mar	NEWA
>A>	AB		EQ 8MG BASE	A090957	002	Mar 29, 2011	Mar	NEWA
>A>	AB		EQ 12MG BASE	A090957	003	Mar 29, 2011	Mar	NEWA
	AB	ZYDUS PHARMS USA INC	EQ 4MG BASE	A078898	001	Feb 17, 2011	Jan	NEWA
	AB		EQ 8MG BASE	A078898	002	Feb 17, 2011	Jan	NEWA
	AB		EQ 12MG BASE	A078898	003	Feb 17, 2011	Jan	NEWA

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE

	+	HOSPIRA INC	EQ 2GM BASE/VIAL	A079183	001	Nov 15, 2010	Feb	CRLD
--	---	-------------	------------------	---------	-----	--------------	-----	------

GEMCITABINE HYDROCHLORIDE

AP		TEVA PARENTERAL	EQ 200MG BASE/VIAL	A077983	002	Jan 25, 2011	Jan	NEWA
AP			EQ 1GM BASE/VIAL	A077983	001	Jan 25, 2011	Jan	NEWA

GEMZAR

AP	+	LILLY	EQ 200MG BASE/VIAL	N020509	001	May 15, 1996	Jan	CFTG
AP	+		EQ 1GM BASE/VIAL	N020509	002	May 15, 1996	Jan	CFTG

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB		BLU CARIBE	600MG	A078012	001	Mar 26, 2007	Feb	CAHN
----	--	------------	-------	---------	-----	--------------	-----	------

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

AT		FERA PHARMS	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb	CAHN
AT		NYCOMED US	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Jan	CAHN

SOLUTION/DROPS; OPHTHALMIC

GENTAMICIN SULFATE

AT		FERA PHARMS	EQ 0.3% BASE	A065121	001	Jan 30, 2004	Feb	CAHN
----	--	-------------	--------------	---------	-----	--------------	-----	------

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB		MYLAN	1MG	A077486	001	Feb 10, 2006	Feb	CAHN
AB			2MG	A077486	002	Feb 10, 2006	Feb	CAHN
AB			4MG	A077486	003	Feb 10, 2006	Feb	CAHN

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB		ZYDUS PHARMS USA INC	2.5MG;250MG	A078905	001	Jan 31, 2011	Jan	NEWA
AB			2.5MG;500MG	A078905	002	Jan 31, 2011	Jan	NEWA
AB			5MG;500MG	A078905	003	Jan 31, 2011	Jan	NEWA

GLYBURIDE

TABLET; ORAL

GLYBURIDE

AB		INDICUS PHARMA	1.25MG	A090937	001	Feb 28, 2011	Feb	NEWA
AB			2.5MG	A090937	002	Feb 28, 2011	Feb	NEWA
AB			5MG	A090937	003	Feb 28, 2011	Feb	NEWA

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

FULVICIN P/G

@ ELORAC 125MG

A061996 001 Jan CAHN

@ 250MG

A061996 002 Jan CAHN

FULVICIN P/G 165

@ ELORAC 165MG

A061996 003 Apr 06, 1982 Jan CAHN

FULVICIN P/G 330

@ ELORAC 330MG

A061996 004 Apr 06, 1982 Jan CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB JUBILANT CADISTA 12.5MG

A078391 001 Feb 11, 2008 Jan CAHN

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB JUBILANT CADISTA 25MG

A040809 001 Sep 04, 2007 Jan CAHN

AB 50MG

A040809 002 Sep 04, 2007 Jan CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB WATSON LABS 12.5MG;50MG

A200180 001 Jan 12, 2011 Jan NEWA

AB 12.5MG;100MG

A200180 002 Jan 12, 2011 Jan NEWA

AB 25MG;100MG

A200180 003 Jan 12, 2011 Jan NEWA

HYDROCORTISONE ACETATE

OINTMENT; OPHTHALMIC

HYDROCORTISONE ACETATE

>D> @ ALTANA 0.5%

A080828 001 Mar CAHN

>A> @ FERA PHARMS 0.5%

A080828 001 Mar CAHN

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

AB ELITE LABS 8MG

A076723 001 Oct 18, 2005 Feb CAHN

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDINE

@ PHARMICS 1%

N000004 004 Jan CAHN

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

MAKENA

+ KV PHARM 1250MG/5ML (250MG/ML)

N021945 001 Feb 03, 2011 Feb NEWA

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

>A> AP SANDOZ 1MG/ML

A091293 001 Mar 29, 2011 Mar NEWA

ILOPERIDONE

TABLET; ORAL

FANAPT

NOVARTIS

2MG

N022192 002 May 06, 2009 Jan CAHN

4MG

N022192 003 May 06, 2009 Jan CAHN

6MG

N022192 004 May 06, 2009 Jan CAHN

8MG

N022192 005 May 06, 2009 Jan CAHN

10MG

N022192 006 May 06, 2009 Jan CAHN

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB

TOLMAR

5%

A091044 001 Feb 28, 2011 Feb NEWA

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

>A>

AB

HETERO DRUGS LTD

25MG

A091240 001 Apr 12, 2011 Mar NEWA

>A>

AB

50MG

A091240 002 Apr 12, 2011 Mar NEWA

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

AB

+

SANDOZ

75MG

A074464 001 May 28, 1998 Jan CTNA

IOFLUPANE I-123

SOLUTION; INTRAVENOUS

DATSCAN

+

GE HLTHCARE INC

5MCI/2.5ML (2MCI/ML)

N022454 001 Jan 14, 2011 Jan NEWA

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200

@ HOSPIRA

41%

A074898 001 Dec 30, 1997 Feb DISC

IOPAMIDOL-200 IN PLASTIC CONTAINER

@ HOSPIRA

41%

A074636 001 Dec 30, 1997 Feb DISC

IOPAMIDOL-250

@ HOSPIRA

51%

A074898 002 Dec 30, 1997 Feb DISC

IOPAMIDOL-250 IN PLASTIC CONTAINER

@ HOSPIRA

51%

A074636 002 Dec 30, 1997 Feb DISC

IOPAMIDOL-300

@ HOSPIRA

61%

A074898 003 Dec 30, 1997 Feb DISC

IOPAMIDOL-300 IN PLASTIC CONTAINER

@ HOSPIRA

61%

A074636 003 Dec 30, 1997 Feb DISC

IOPAMIDOL-370

@ HOSPIRA

76%

A074898 004 Dec 30, 1997 Feb DISC

IOPAMIDOL-370 IN PLASTIC CONTAINER

@ HOSPIRA

76%

A074636 004 Dec 30, 1997 Feb DISC

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

AB

MIKAH PHARMA

2.5MG

A077169 001 Apr 24, 2006 Feb CAHN

AB

5MG

A077169 002 Apr 24, 2006 Feb CAHN

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

>A>	AB	ACTAVIS TOTOWA	25MG	A078669 001	Apr 08, 2011	Mar	NEWA
>A>	AB		100MG	A078669 002	Apr 08, 2011	Mar	NEWA
>A>	AB		150MG	A078669 003	Apr 08, 2011	Mar	NEWA
>A>	AB		200MG	A078669 004	Apr 08, 2011	Mar	NEWA
	AB	ALEMBIC LTD	25MG	A090607 001	Jan 13, 2011	Jan	NEWA
	AB		100MG	A090607 002	Jan 13, 2011	Jan	NEWA
	AB		150MG	A090607 003	Jan 13, 2011	Jan	NEWA
	AB		200MG	A090607 004	Jan 13, 2011	Jan	NEWA

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

	AB	JUBILANT LIFE	5MG	A200220 001	Feb 28, 2011	Feb	NEWA
	AB		25MG	A200220 002	Feb 28, 2011	Feb	NEWA

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

>A>	AT	ALCON RES	0.005%	A091449 001	Mar 22, 2011	Mar	NEWA
>A>	AT	APOTEX	0.005%	A077697 001	Mar 22, 2011	Mar	NEWA
>A>	AT	BAUSCH AND LOMB	0.005%	A201006 001	Mar 22, 2011	Mar	NEWA
>A>	AT	MYLAN	0.005%	A201786 001	Mar 22, 2011	Mar	NEWA
>A>	AT	PHARMAFORCE	0.005%	A200925 001	Mar 22, 2011	Mar	NEWA

XALATAN

>D>	+	PHARMACIA AND UPJOHN	0.005%	N020597 001	Jun 05, 1996	Mar	CFTG
>A>	AT	+	0.005%	N020597 001	Jun 05, 1996	Mar	CFTG

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

	AB	ACCORD HLTHCARE	250MG	A090843 001	Feb 14, 2011	Jan	NEWA
	AB		500MG	A090843 002	Feb 14, 2011	Jan	NEWA
	AB		750MG	A090843 003	Feb 14, 2011	Jan	NEWA
	AB		1GM	A090843 004	Feb 14, 2011	Jan	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

	AB	DR REDDYS LABS LTD	5MG	A090392 001	Feb 24, 2011	Feb	NEWA
	AB	GLENMARK GENERICS	5MG	A090385 001	Feb 24, 2011	Feb	NEWA

LEVOFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

	AT	HI TECH PHARMA	0.5%	A076826 001	Feb 10, 2011	Jan	NEWA
--	----	----------------	------	-------------	--------------	-----	------

LEVONORGESTREL

TABLET; ORAL

PLAN B

@ TEVA WOMENS

			0.75MG	N021045 001	Jul 28, 1999	Feb	CAHN
AB	+		0.75MG	N021045 002	Aug 24, 2006	Feb	CAHN

LEVORPHANOL TARTRATE

TABLET; ORAL

>D> LEVO-DROMORAN

>D> AB + VALEANT PHARM INTL 2MG N008720 001 Dec 19, 1991 Mar DISC

>A> @ 2MG N008720 001 Dec 19, 1991 Mar DISC

LEVORPHANOL TARTRATE

>D> AB ROXANE 2MG A074278 001 Mar 31, 2000 Mar CTEC

>A> 2MG A074278 001 Mar 31, 2000 Mar CTEC

LEVOTHYROXINE SODIUM**

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL

LEVO-T

AB1, ALARA PHARM 0.025MG N021342 001 Mar 01, 2002 Feb CTEC
AB2,
AB3AB1, 0.05MG N021342 002 Mar 01, 2002 Feb CTEC
AB2,
AB3AB1, 0.075MG N021342 003 Mar 01, 2002 Feb CTEC
AB2,
AB3AB1, 0.088MG N021342 004 Mar 01, 2002 Feb CTEC
AB2,
AB3AB1, 0.1MG N021342 005 Mar 01, 2002 Feb CTEC
AB2,
AB3AB1, 0.112MG N021342 006 Mar 01, 2002 Feb CTEC
AB2,
AB3AB1, 0.125MG N021342 007 Mar 01, 2002 Feb CTEC
AB2,
AB3AB1, 0.137MG N021342 012 Dec 08, 2003 Feb CTEC
AB2,
AB3AB1, 0.15MG N021342 008 Mar 01, 2002 Feb CTEC
AB2,
AB3AB1, 0.175MG N021342 009 Mar 01, 2002 Feb CTEC
AB2,
AB3AB1, 0.2MG N021342 010 Mar 01, 2002 Feb CTEC
AB2,
AB3AB1, + 0.3MG N021342 011 Mar 01, 2002 Feb CTEC
AB2,
AB3LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL

LIDOCAINE HYDROCHLORIDE

>A> AT HI TECH PHARMA 2% A040837 001 Mar 23, 2011 Mar NEWA

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB GLENMARK GENERICS 450MG A091616 001 Feb 14, 2011 Jan NEWA

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB	MYLAN	25MG	A091590 001	Oct 06, 2010	Jan	NEWA
AB		50MG	A091590 002	Oct 06, 2010	Jan	NEWA
AB		100MG	A091590 003	Oct 06, 2010	Jan	NEWA

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	12.5MG	A201451 001	Feb 23, 2011	Feb	NEWA
AA		25MG	A201451 002	Feb 23, 2011	Feb	NEWA
AA		50MG	A201451 003	Feb 23, 2011	Feb	NEWA
AA	JUBILANT CADISTA	12.5MG	A040659 001	Jun 04, 2010	Jan	CAHN
AA		25MG	A040659 002	Jun 04, 2010	Jan	CAHN

MELOXICAM

TABLET; ORAL

MELOXICAM

AB	MYLAN	7.5MG	A077934 001	Jul 20, 2006	Feb	CAHN
AB		15MG	A077934 002	Jul 20, 2006	Feb	CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

>A>	AP	SANDOZ	500MG/VIAL	A091201 001	Mar 29, 2011	Mar	NEWA
>A>	AP		1GM/VIAL	A091201 002	Mar 29, 2011	Mar	NEWA
>A>		MERREM					
>A>	AP	+ ASTRAZENECA	500MG/VIAL	N050706 003	Jun 21, 1996	Mar	CTNA
>A>	AP	+	1GM/VIAL	N050706 001	Jun 21, 1996	Mar	CTNA
>D>		MERREM I.V.					
>D>	AP	+ ASTRAZENECA	500MG/VIAL	N050706 003	Jun 21, 1996	Mar	CTNA
>D>	AP	+	1GM/VIAL	N050706 001	Jun 21, 1996	Mar	CTNA

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	MYLAN	500MG	A075973 001	Jan 25, 2002	Feb	CAHN
AB		850MG	A075973 002	Jan 25, 2002	Feb	CAHN
AB		1GM	A075973 003	Jan 25, 2002	Feb	CAHN

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

AB	TAKEDA GLOBAL	500MG;EQ 15MG BASE	N021842 001	Aug 29, 2005	Feb	CFTG
AB	+	850MG;EQ 15MG BASE	N021842 002	Aug 29, 2005	Feb	CFTG
		PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE				
AB	MYLAN	500MG;EQ 15MG BASE	A090406 001	Feb 25, 2011	Feb	NEWA
AB		850MG;EQ 15MG BASE	A090406 002	Feb 25, 2011	Feb	NEWA

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

AB	JUBILANT CADISTA	4MG	A040189 001	Oct 31, 1997	Jan	CAHN
AB		8MG	A040189 002	Oct 31, 1997	Jan	CAHN

TABLET; ORAL									
METHYLPREDNISOLONE									
AB	JUBILANT CADISTA	16MG	A040189	003	Jul 20, 2007	Jan	CAHN		
AB		32MG	A040189	004	Jul 20, 2007	Jan	CAHN		
<u>METHYLPREDNISOLONE SODIUM SUCCINATE</u>									
INJECTABLE; INJECTION									
A-METHAPRED									
	@ HOSPIRA	EQ 500MG BASE/VIAL	A089173	001	Aug 18, 1987	Feb	DISC		
	@	EQ 1GM BASE/VIAL	A089174	001	Aug 18, 1987	Feb	DISC		
<u>METRONIDAZOLE</u>									
GEL; TOPICAL									
METRONIDAZOLE									
AB	G AND W LABS INC	0.75%	A078178	001	Jan 19, 2011	Jan	NEWA		
<u>MICAFUNGIN SODIUM</u>									
INJECTABLE; IV (INFUSION)									
MYCAMINE									
+	ASTELLAS	100MG/VIAL	N021506	003	Jun 27, 2006	Jan	CRLD		
<u>MILRINONE LACTATE</u>									
INJECTABLE; INJECTION									
MILRINONE LACTATE									
	@ HOSPIRA	EQ 1MG BASE/ML	A075884	001	May 28, 2002	Feb	DISC		
<u>MIRTAZAPINE</u>									
TABLET, ORALLY DISINTEGRATING; ORAL									
MIRTAZAPINE									
AB	ACTAVIS ELIZABETH	15MG	A077959	001	Feb 14, 2011	Jan	NEWA		
AB		30MG	A077959	002	Feb 14, 2011	Jan	NEWA		
AB		45MG	A077959	003	Feb 14, 2011	Jan	NEWA		
<u>MUPIROCIN CALCIUM</u>									
CREAM; TOPICAL									
BACTROBAN									
+	GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Jan	CDFR		
<u>NABUMETONE</u>									
TABLET; ORAL									
NABUMETONE									
AB	LUPIN LTD	500MG	A090445	001	Jan 12, 2011	Jan	NEWA		
AB		750MG	A090445	002	Jan 12, 2011	Jan	NEWA		
<u>NALTREXONE HYDROCHLORIDE</u>									
TABLET; ORAL									
NALTREXONE HYDROCHLORIDE									
AB	ELITE LABS	50MG	A075274	001	May 26, 1999	Feb	CAHN		
<u>NAPROXEN</u>									
TABLET; ORAL									
NAPROXEN									
AB	MARKSANS PHARMA	250MG	A091416	001	Feb 14, 2011	Jan	NEWA		
AB		375MG	A091416	002	Feb 14, 2011	Jan	NEWA		
AB		500MG	A091416	003	Feb 14, 2011	Jan	NEWA		

NARATRIPTAN

TABLET; ORAL

NARATRIPTAN

AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552 001	Feb 14, 2011	Jan	NEWA
----	--------------------	---------------	-------------	--------------	-----	------

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB	INDICUS PHARMA	EQ 1MG BASE	A200502 001	Feb 28, 2011	Feb	NEWA
----	----------------	-------------	-------------	--------------	-----	------

AB		EQ 2.5MG BASE	A200502 002	Feb 28, 2011	Feb	NEWA
----	--	---------------	-------------	--------------	-----	------

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

>A>	AB	WATSON LABS	60MG	A077462 001	Mar 30, 2011	Mar	NEWA
-----	----	-------------	------	-------------	--------------	-----	------

>A>	AB		120MG	A077462 002	Mar 30, 2011	Mar	NEWA
-----	----	--	-------	-------------	--------------	-----	------

NEVIRAPINE

>A>	TABLET, EXTENDED RELEASE; ORAL	
-----	--------------------------------	--

>A>	VIRAMUNE XR	
-----	-------------	--

>A>	+	BOEHRINGER INGELHEIM	400MG	N201152 001	Mar 25, 2011	Mar	NEWA
-----	---	----------------------	-------	-------------	--------------	-----	------

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

NISOLDIPINE

AB	MYLAN	8.5MG	A091001 001	Jan 26, 2011	Jan	NEWA
----	-------	-------	-------------	--------------	-----	------

AB		17MG	A091001 002	Jan 26, 2011	Jan	NEWA
----	--	------	-------------	--------------	-----	------

AB		25.5MG	A091001 003	Jan 26, 2011	Jan	NEWA
----	--	--------	-------------	--------------	-----	------

AB		34MG	A091001 004	Jan 26, 2011	Jan	NEWA
----	--	------	-------------	--------------	-----	------

SULAR

AB	+	SHIONOGI PHARMA	8.5MG	N020356 008	Jan 02, 2008	Jan	CFTG
----	---	-----------------	-------	-------------	--------------	-----	------

AB	+		17MG	N020356 007	Jan 02, 2008	Jan	CFTG
----	---	--	------	-------------	--------------	-----	------

AB		25.5MG	N020356 006	Jan 02, 2008	Jan	CFTG
----	--	--------	-------------	--------------	-----	------

AB	+		34MG	N020356 005	Jan 02, 2008	Jan	CFTG
----	---	--	------	-------------	--------------	-----	------

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

AB	MYLAN	150MG	A075934 001	Jul 09, 2002	Feb	CAHN
----	-------	-------	-------------	--------------	-----	------

AB		300MG	A075934 002	Jul 09, 2002	Feb	CAHN
----	--	-------	-------------	--------------	-----	------

NYSTATIN

SUSPENSION; ORAL

NYSTATIN

AA	VISTAPHARM	100,000 UNITS/ML	A065422 001	Mar 07, 2011	Feb	NEWA
----	------------	------------------	-------------	--------------	-----	------

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP	BIONICHE PHARMA USA	EQ 0.05MG BASE/ML	A079198 001	Feb 10, 2011	Jan	NEWA
----	---------------------	-------------------	-------------	--------------	-----	------

AP		EQ 0.1MG BASE/ML	A079198 002	Feb 10, 2011	Jan	NEWA
----	--	------------------	-------------	--------------	-----	------

AP		EQ 0.5MG BASE/ML	A079198 003	Feb 10, 2011	Jan	NEWA
----	--	------------------	-------------	--------------	-----	------

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

AB	RANBAXY	4MG	A078602 001	Feb 24, 2011	Feb	NEWA
AB		8MG	A078602 002	Feb 24, 2011	Feb	NEWA

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP	TEVA	EQ 2MG BASE/ML	A076876 001	Nov 22, 2006	Jan	CMFD
----	------	----------------	-------------	--------------	-----	------

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 4MG BASE/5ML	A091483 001	Jan 31, 2011	Jan	NEWA
----	---------------	-----------------	-------------	--------------	-----	------

AA	SILARX	EQ 4MG BASE/5ML	A091342 001	Jan 27, 2011	Jan	NEWA
----	--------	-----------------	-------------	--------------	-----	------

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

>A>	AB	TARO	EQ 4MG BASE	A077729 001	Mar 28, 2011	Mar	NEWA
>A>	AB		EQ 8MG BASE	A077729 002	Mar 28, 2011	Mar	NEWA
>A>	AB		EQ 24MG BASE	A077729 003	Mar 28, 2011	Mar	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP	SANDOZ	50MG/10ML (5MG/ML)	A078817 001	Jan 24, 2011	Jan	NEWA
----	--------	--------------------	-------------	--------------	-----	------

AP		100MG/20ML (5MG/ML)	A078817 002	Jan 24, 2011	Jan	NEWA
----	--	---------------------	-------------	--------------	-----	------

OXAPROZIN

TABLET; ORAL

OXAPROZIN

AB	MYLAN	600MG	A075847 001	Feb 28, 2001	Feb	CAHN
----	-------	-------	-------------	--------------	-----	------

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB	COASTAL PHARMS	5MG	A091313 001	Feb 18, 2011	Feb	NEWA
----	----------------	-----	-------------	--------------	-----	------

AB		15MG	A091313 002	Feb 18, 2011	Feb	NEWA
----	--	------	-------------	--------------	-----	------

AB		30MG	A091313 003	Feb 18, 2011	Feb	NEWA
----	--	------	-------------	--------------	-----	------

AB	RHODES PHARMS	5MG	A091490 001	Mar 09, 2011	Feb	NEWA
----	---------------	-----	-------------	--------------	-----	------

AB		10MG	A091490 002	Mar 09, 2011	Feb	NEWA
----	--	------	-------------	--------------	-----	------

AB		15MG	A091490 003	Mar 09, 2011	Feb	NEWA
----	--	------	-------------	--------------	-----	------

AB		20MG	A091490 004	Mar 09, 2011	Feb	NEWA
----	--	------	-------------	--------------	-----	------

AB		30MG	A091490 005	Mar 09, 2011	Feb	NEWA
----	--	------	-------------	--------------	-----	------

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

AB	TEVA	5MG	A091443 002	Feb 15, 2011	Jan	NEWA
----	------	-----	-------------	--------------	-----	------

AB		10MG	A091443 001	Feb 15, 2011	Jan	NEWA
----	--	------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

@ ENDO PHARMS

7.5MG

N021610 005	Feb 29, 2008	Feb	DISC
-------------	--------------	-----	------

@

15MG

N021610 006	Feb 29, 2008	Feb	DISC
-------------	--------------	-----	------

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	ACTAVIS TOTOWA	EQ 20MG BASE	A090797 001	Feb 07, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090797 002	Feb 07, 2011	Jan	NEWA
AB	DR REDDYS LABS LTD	EQ 20MG BASE	A077619 001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A077619 002	Jan 19, 2011	Jan	NEWA
AB	KUDCO IRELAND	EQ 20MG BASE	A078281 001	Jan 20, 2011	Jan	NEWA
AB		EQ 40MG BASE	A078281 002	Jan 20, 2011	Jan	NEWA
AB	MATRIX LABS LTD	EQ 20MG BASE	A090970 001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090970 002	Jan 19, 2011	Jan	NEWA
AB	TORRENT PHARMS	EQ 20MG BASE	A090074 001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090074 002	Jan 19, 2011	Jan	NEWA
AB	WOCKHARDT	EQ 20MG BASE	A091231 001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A091231 002	Jan 19, 2011	Jan	NEWA

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

AA	EPIC PHARMA LLC	37.5MG	A200272 001	Jan 31, 2011	Jan	NEWA
----	-----------------	--------	-------------	--------------	-----	------

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	HOSPIRA INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386 001	Sep 15, 2009	Jan	CAHN
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386 002	Sep 15, 2009	Jan	CAHN
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386 003	Sep 15, 2009	Jan	CAHN
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446 001	Sep 15, 2009	Jan	CAHN

PIROXICAM

CAPSULE; ORAL

PIROXICAM

@ MYLAN	10MG	A074043 001	Sep 22, 1992	Feb	CAHN
@	20MG	A074043 002	Sep 22, 1992	Feb	CAHN

PREDNISONE

TABLET; ORAL

PREDNISONE

AB	JUBILANT CADISTA	1MG	A040611 001	Jun 06, 2005	Jan	CAHN
AB		5MG	A040362 002	Aug 29, 2001	Jan	CAHN
AB		10MG	A040362 001	Aug 29, 2001	Jan	CAHN
AB		20MG	A040362 003	Jun 29, 2005	Jan	CAHN

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCOMP

AB	JUBILANT CADISTA	EQ 5MG BASE	A040268 001	Feb 27, 1998	Jan	CAHN
AB		EQ 10MG BASE	A040268 002	Feb 27, 1998	Jan	CAHN

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

+	ROXANE	15MG	A080927 002		Jan	CMFD
---	--------	------	-------------	--	-----	------

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON

@	XANODYNE PHARM	65MG	N010997 003		Jan	DISC
---	----------------	------	-------------	--	-----	------

PROPOXYPHENE HYDROCHLORIDE

>D>	AA	TEVA	65MG	A088615 001	Oct 22, 1984	Mar	DISC
-----	----	------	------	-------------	--------------	-----	------

>A>		@	65MG	A088615 001	Oct 22, 1984	Mar	DISC
-----	--	---	------	-------------	--------------	-----	------

>D>	AA	VINTAGE PHARMS	65MG	A040908 001	Jul 17, 2009	Mar	DISC
-----	----	----------------	------	-------------	--------------	-----	------

>A>		@	65MG	A040908 001	Jul 17, 2009	Mar	DISC
-----	--	---	------	-------------	--------------	-----	------

		@ WEST WARD	65MG	A083501 001		Jan	DISC
--	--	-------------	------	-------------	--	-----	------

PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVON-N

@	XANODYNE PHARM	100MG	N016862 002		Jan	DISC
---	----------------	-------	-------------	--	-----	------

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

>A>	AB	ZYDUS PHARMS USA INC	60MG	A090321 001	Mar 25, 2011	Mar	NEWA
-----	----	----------------------	------	-------------	--------------	-----	------

>A>	AB		80MG	A090321 002	Mar 25, 2011	Mar	NEWA
-----	----	--	------	-------------	--------------	-----	------

>A>	AB		120MG	A090321 003	Mar 25, 2011	Mar	NEWA
-----	----	--	-------	-------------	--------------	-----	------

>A>	AB		160MG	A090321 004	Mar 25, 2011	Mar	NEWA
-----	----	--	-------	-------------	--------------	-----	------

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

>A>	AB	MYLAN	60MG	A070213 005	Apr 08, 2011	Mar	NEWA
-----	----	-------	------	-------------	--------------	-----	------

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

AB	MYLAN	EQ 5MG BASE	A076036 001	Jan 28, 2005	Feb	CAHN
----	-------	-------------	-------------	--------------	-----	------

AB		EQ 10MG BASE	A076036 002	Jan 28, 2005	Feb	CAHN
----	--	--------------	-------------	--------------	-----	------

AB		EQ 20MG BASE	A076036 003	Jan 28, 2005	Feb	CAHN
----	--	--------------	-------------	--------------	-----	------

AB		EQ 40MG BASE	A076036 004	Jan 28, 2005	Feb	CAHN
----	--	--------------	-------------	--------------	-----	------

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

@	MYLAN	EQ 150MG BASE	A075564 001	Oct 27, 2000	Feb	CAHN
---	-------	---------------	-------------	--------------	-----	------

@		EQ 300MG BASE	A075564 002	Oct 27, 2000	Feb	CAHN
---	--	---------------	-------------	--------------	-----	------

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

>A>	AA	HI TECH PHARMA	EQ 15MG BASE/ML	A091078 001	Mar 22, 2011	Mar	NEWA
-----	----	----------------	-----------------	-------------	--------------	-----	------

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

AB	MYLAN	EQ 150MG BASE	A074023 001	Aug 22, 1997	Feb	CAHN
----	-------	---------------	-------------	--------------	-----	------

AB		EQ 300MG BASE	A074023 002	Aug 22, 1997	Feb	CAHN
----	--	---------------	-------------	--------------	-----	------

RIFAXIMIN

TABLET; ORAL
XIFAXAN

+ SALIX PHARMS 550MG N022554 001 Mar 24, 2010 Feb CRLD

RISPERIDONE

SOLUTION; ORAL
RISPERIDONE

AA TARO 1MG/ML A090347 001 Feb 07, 2011 Jan NEWA

TABLET; ORAL

RISPERIDONE

@ RATIOPHARM

@

@

@

@

@

@

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

>A> AB MYLAN 0.5MG A091537 001 Mar 30, 2011 Mar NEWA

>A> AB 1MG A091537 002 Mar 30, 2011 Mar NEWA

>A> AB 2MG A091537 003 Mar 30, 2011 Mar NEWA

>A> AB 3MG A091537 004 Mar 30, 2011 Mar NEWA

>A> AB 4MG A091537 005 Mar 30, 2011 Mar NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP SAGENT STRIDES 50MG/5ML (10MG/ML) A091458 001 Jul 28, 2010 Jan CAHN

AP 100MG/10ML (10MG/ML) A091458 002 Jul 28, 2010 Jan CAHN

ROFLUMILAST

TABLET; ORAL

DALIRESP

+ FOREST RES INST INC 500MCG N022522 001 Feb 28, 2011 Feb NEWA

RUFINAMIDE

>A> SUSPENSION; ORAL

>A> BANZEL

>A> + EISAI INC 40MG/ML N201367 001 Mar 03, 2011 Mar NEWA

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECONAL SODIUM

+ MARATHON PHARMS 50MG A086101 001 Oct 03, 1983 Jan CAHN

+ 100MG A086101 002 Oct 03, 1983 Jan CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

>D> AA ROXANE EQ 20MG BASE/ML A076934 001 Jun 30, 2006 Mar DISC

>A> @ EQ 20MG BASE/ML A076934 001 Jun 30, 2006 Mar DISC

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB MYLAN EQ 25MG BASE A076540 001 Mar 20, 2007 Feb CAHN

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB	MYLAN	EQ 50MG BASE	A076540 002	Mar 20, 2007	Feb	CAHN
AB		EQ 100MG BASE	A076540 003	Mar 20, 2007	Feb	CAHN
>D>	AB	ROXANE	EQ 25MG BASE	A076881 001	Feb 06, 2007	Mar DISC
>A>	@	EQ 25MG BASE	A076881 001	Feb 06, 2007	Mar DISC	
>D>	AB	EQ 50MG BASE	A076881 002	Feb 06, 2007	Mar DISC	
>A>	@	EQ 50MG BASE	A076881 002	Feb 06, 2007	Mar DISC	
>D>	AB	EQ 100MG BASE	A076881 003	Feb 06, 2007	Mar DISC	
>A>	@	EQ 100MG BASE	A076881 003	Feb 06, 2007	Mar DISC	

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

>D>	+	SANOFI AVENTIS US	62.5MG/5ML	N020955 001	Feb 18, 1999	Mar CFTG
>A>	AB	+	62.5MG/5ML	N020955 001	Feb 18, 1999	Mar CFTG
>A>		SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE				
>A>	AB	GENERAMEDIX	62.5MG/5ML	A078215 001	Mar 31, 2011	Mar NEWA

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F 18

+	NIH NCI DCTD	10-200mCi/ML	N022494 001	Jan 26, 2011	Jan	NEWA
---	--------------	--------------	-------------	--------------	-----	------

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS

NITHIODOTE

+	HOPE PHARMS	300MG/10ML (30MG/ML), N/A; N/A, 12.5G M/50ML (250MG/ML)	N201444 001	Jan 14, 2011	Feb	CTNA
---	-------------	---	-------------	--------------	-----	------

SODIUM NITRITE

+	HOPE PHARMS	300MG/10ML (30MG/ML), N/A; N/A, 12.5G M/50ML (250MG/ML)	N201444 001	Jan 14, 2011	Jan	NEWA
---	-------------	---	-------------	--------------	-----	------

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+	PARAPRO PHARMS	0.9%	N022408 001	Jan 18, 2011	Jan	NEWA
---	----------------	------	-------------	--------------	-----	------

SUMATRIPTAN SUCCINATE

TABLET; ORAL

SUMATRIPTAN SUCCINATE

>D>	AB	ROXANE	EQ 25MG BASE	A078241 001	Aug 10, 2009	Mar DISC
>A>	@	EQ 25MG BASE	A078241 001	Aug 10, 2009	Mar DISC	
>D>	AB	EQ 50MG BASE	A078241 002	Aug 10, 2009	Mar DISC	
>A>	@	EQ 50MG BASE	A078241 002	Aug 10, 2009	Mar DISC	
>D>	AB	EQ 100MG BASE	A078241 003	Aug 10, 2009	Mar DISC	
>A>	@	EQ 100MG BASE	A078241 003	Aug 10, 2009	Mar DISC	

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB	JUBILANT CADISTA	EQ 1MG BASE	A075317 001	Dec 20, 2004	Jan	CAHN
AB		EQ 2MG BASE	A075317 002	Dec 20, 2004	Jan	CAHN
AB		EQ 5MG BASE	A075317 003	Dec 20, 2004	Jan	CAHN
AB		EQ 10MG BASE	A075317 004	Dec 20, 2004	Jan	CAHN

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

AB	MYLAN	EQ 250MG BASE	A077136 001	Jul 02, 2007	Feb	CAHN
	@ ROXANE	EQ 250MG BASE	A077223 001	Jul 02, 2007	Feb	DISC

TERBUTALINE SULFATE

TABLET; ORAL

TERBUTALINE SULFATE

AB	+ IMPAX LABS	5MG	A075877 002	Jun 26, 2001	Jan	CRLD
----	--------------	-----	-------------	--------------	-----	------

TESTOSTERONE

GEL, METERED; TRANSDERMAL

FORTESTA

>D>	+ ENDO PHARMS	10MG/5GM ACTIVATION	N021463 001	Dec 29, 2010	Mar	CPOT
>A>	+	10MG/0.5GM ACTIVATION	N021463 001	Dec 29, 2010	Mar	CPOT

THEOPHYLLINE

SOLUTION; ORAL

THEOPHYLLINE

>A>	+ SILARX	80MG/15ML	A091156 001	Apr 13, 2011	Mar	NEWA
-----	----------	-----------	-------------	--------------	-----	------

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

AB	MYLAN	250MG	A075161 001	Sep 13, 1999	Feb	CAHN
----	-------	-------	-------------	--------------	-----	------

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

>D>	AT	ALTANA	0.3%	A065026 001	Sep 11, 2001	Mar	CAHN
>A>	AT	FERA PHARMS	0.3%	A065026 001	Sep 11, 2001	Mar	CAHN

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

AP	DR REDDYS LABS LTD	EQ 4MG BASE/VIAL	A201191 001	Mar 09, 2011	Feb	NEWA
AP	SAGENT PHARMS	EQ 4MG BASE/VIAL	A091284 001	Jan 26, 2011	Jan	NEWA

SOLUTION; INTRAVENOUS

TOPOTECAN

AP	HOSPIRA INC	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200582 001	Feb 02, 2011	Feb	NEWA
	SANDOZ	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N200199 001	Feb 25, 2011	Feb	NEWA
		EQ 3MG BASE/3ML (EQ 1MG BASE/ML)	N200199 002	Feb 25, 2011	Feb	NEWA
AP	+	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200199 003	Feb 25, 2011	Feb	NEWA

TORSEMIDE

TABLET; ORAL

TORSEMIDE

>A>	AB	VINTAGE PHARMS	5MG	A090613 001	Mar 22, 2011	Mar	NEWA
>A>	AB		10MG	A090613 002	Mar 22, 2011	Mar	NEWA
>A>	AB		20MG	A090613 003	Mar 22, 2011	Mar	NEWA
>A>	AB		100MG	A090613 004	Mar 22, 2011	Mar	NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	50MG	A090404	001	Jan 31, 2011	Jan	NEWA
----	----------------------	------	---------	-----	--------------	-----	------

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

AP	PHARMAFORCE	100MG/ML	A091330	001	Mar 08, 2011	Feb	NEWA
----	-------------	----------	---------	-----	--------------	-----	------

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

AP	PHARMAFORCE	100MG/ML	A091329	001	Mar 08, 2011	Feb	NEWA
----	-------------	----------	---------	-----	--------------	-----	------

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

AB	MIKAH PHARMA	EQ 25MG BASE	A077361	001	Aug 02, 2006	Feb	CAHN
----	--------------	--------------	---------	-----	--------------	-----	------

AB		EQ 50MG BASE	A077361	002	Aug 02, 2006	Feb	CAHN
----	--	--------------	---------	-----	--------------	-----	------

AB		EQ 100MG BASE	A077361	003	Aug 02, 2006	Feb	CAHN
----	--	---------------	---------	-----	--------------	-----	------

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	ACTAVIS PHARMA	EQ 500MG BASE	A090370	001	Mar 16, 2011	Feb	NEWA
----	----------------	---------------	---------	-----	--------------	-----	------

AB		EQ 1GM BASE	A090370	002	Mar 16, 2011	Feb	NEWA
----	--	-------------	---------	-----	--------------	-----	------

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

TROVIS PHARMS

10MG

N022567	001	Jan 21, 2011	Jan	NEWA
---------	-----	--------------	-----	------

20MG

N022567	002	Jan 21, 2011	Jan	NEWA
---------	-----	--------------	-----	------

+

40MG

N022567	003	Jan 21, 2011	Jan	NEWA
---------	-----	--------------	-----	------

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCRISTINE SULFATE

@ APP PHARMS

1MG/ML

A076401	001	Oct 28, 2003	Jan	DISC
---------	-----	--------------	-----	------

ZIDOVUDINE

INJECTABLE; INJECTION

ZIDOVUDINE

AP	LUITPOLD	10MG/ML	A091457	001	May 06, 2010	Feb	CAHN
----	----------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

ZIDOVUDINE

@ MATRIX LABS LTD

100MG

N200732	001	Feb 23, 2011	Feb	NEWA
---------	-----	--------------	-----	------

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

AB	MYLAN	5MG	A078016	001	Apr 23, 2007	Feb	CAHN
----	-------	-----	---------	-----	--------------	-----	------

AB		10MG	A078016	002	Apr 23, 2007	Feb	CAHN
----	--	------	---------	-----	--------------	-----	------

OTC DRUG PRODUCT LIST - 31ST EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

2-1

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

MYLAN

10MG

A075674 001 Dec 21, 2001 Feb CAHN

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US 30MG/5ML

N201373 001 Jan 24, 2011 Jan NEWA

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US 30MG/5ML

N201373 002 Jan 24, 2011 Jan NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US 30MG

N021909 002 Jan 24, 2011 Jan NEWA

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US 30MG

N021909 003 Jan 24, 2011 Jan NEWA

TABLET; ORAL

ALLEGRA ALLERGY

SANOFI AVENTIS US 60MG

N020872 007 Jan 24, 2011 Jan NEWA

+ 180MG

N020872 010 Jan 24, 2011 Jan NEWA

ALLEGRA HIVES

SANOFI AVENTIS US 60MG

N020872 008 Jan 24, 2011 Jan NEWA

+ 180MG

N020872 009 Jan 24, 2011 Jan NEWA

CHILDREN'S ALLEGRA ALLERGY

SANOFI AVENTIS US 30MG

N020872 005 Jan 24, 2011 Jan NEWA

CHILDREN'S ALLEGRA HIVES

SANOFI AVENTIS US 30MG

N020872 006 Jan 24, 2011 Jan NEWA

>A> CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

>A> DR REDDYS LABS LTD 30MG

A076502 004 Apr 12, 2011 Mar NEWA

>A> TEVA 30MG

A076447 004 Apr 13, 2011 Mar NEWA

>A> CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

>A> DR REDDYS LABS LTD 30MG

A076502 005 Apr 12, 2011 Mar NEWA

>A> TEVA 30MG

A076447 005 Apr 13, 2011 Mar NEWA

>A> FEXOFENADINE HYDROCHLORIDE ALLERGY

>A> DR REDDYS LABS LTD 60MG

A076502 006 Apr 12, 2011 Mar NEWA

>A> 180MG

A076502 008 Apr 12, 2011 Mar NEWA

>A> TEVA 60MG

A076447 006 Apr 13, 2011 Mar NEWA

>A> 180MG

A076447 008 Apr 13, 2011 Mar NEWA

>A> FEXOFENADINE HYDROCHLORIDE HIVES

>A> DR REDDYS LABS LTD 60MG

A076502 007 Apr 12, 2011 Mar NEWA

>A> 180MG

A076502 009 Apr 12, 2011 Mar NEWA

>A> TEVA 60MG

A076447 007 Apr 13, 2011 Mar NEWA

>A> 180MG

A076447 009 Apr 13, 2011 Mar NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US 60MG;120MG

N020786 002 Jan 24, 2011 Jan NEWA

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US 180MG;240MG

N021704 002 Jan 24, 2011 Jan NEWA

IBUPROFEN

TABLET; ORAL

IBUPROFEN

	MARKSANS PHARMA	200MG	A091237 001	Feb 08, 2011	Jan	NEWA
		200MG	A091239 001	Feb 01, 2011	Jan	NEWA
	MERRO PHARM	200MG	A070985 001	Oct 02, 1987	Jan	CAHN
>A>	SVADS HOLDINGS SA	200MG	A079129 001	Mar 28, 2011	Mar	NEWA
>A>		200MG	A091355 001	Apr 04, 2011	Mar	NEWA

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

NOVOLIN N

+	NOVO NORDISK INC	100 UNITS/ML	N019959 001	Jul 01, 1991	Jan	CRLD
---	------------------	--------------	-------------	--------------	-----	------

LEVONORGESTREL

TABLET; ORAL

PLAN B

+	TEVA WOMENS	0.75MG	N021045 002	Aug 24, 2006	Feb	CAHN
---	-------------	--------	-------------	--------------	-----	------

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

	MARKSANS PHARMA	EQ 200MG BASE	A090545 001	Mar 16, 2011	Feb	NEWA
--	-----------------	---------------	-------------	--------------	-----	------

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

	MYLAN	EQ 75MG BASE	A075497 001	Jan 14, 2000	Feb	CAHN
--	-------	--------------	-------------	--------------	-----	------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 3 MARCH 2011

NO MARCH 2011 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MARCH 2011 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST - 31ST EDITION

A - 1

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAPALENE - DIFFERIN</u>						
N021753 001	7868044	Mar 12, 2023	U-1078			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 001					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 002					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 003					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 004					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 001	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 002	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 003	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 004	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 005	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	5250542	Mar 29, 2016	DS DP U-878			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE</u>						
A078381 005					PC	Jul 02, 2011
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE</u>						
A078381 006					PC	Jul 02, 2011
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10</u>						
N021303 001	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u>						
N021303 006	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20</u>						
N021303 002	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25</u>						
N021303 004	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u>						
N021303 003	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5</u>						
N021303 005	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 001					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 002					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 003					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 004					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 005					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 006					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021713 001					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021729 002					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021729 003					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021866 001					I-633	Feb 16, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 001					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 002					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 003					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 004					D-130	Feb 04, 2014
<u>AZILSARTAN MEDOXOMIL - EDARBI</u>						
N200796 001	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZILSARTAN MEDOXOMIL - EDARBI</u>						
N200796 002	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZITHROMYCIN - ZMAX</u>						
N050797 001	7887844	Feb 14, 2024	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	>A> 7897646	Sep 09, 2018	U-1118			
<u>CELECOXIB - CELEBREX</u>						
N020998 001	5760068	Jun 02, 2015	U-672			
<u>CELECOXIB - CELEBREX</u>						
N020998 002	5760068	Jun 02, 2015	U-672			
<u>CELECOXIB - CELEBREX</u>						
N020998 003	5760068	Jun 02, 2015	U-672			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 001					I-634 M-101 >A> ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 002					I-634 M-101 >A> ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 003					I-634 M-101 >A> ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N020839 001	4847265	Nov 17, 2011	DS DP			
	4847265*PED	May 17, 2012				
	5576328	Jan 31, 2014	U-432	Y		
	5576328*PED	Jul 31, 2014				
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N020839 002	4847265	Nov 17, 2011	DS DP			
	4847265*PED	May 17, 2012				
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
<u>COLCHICINE - COLCRYS</u>						
N022352 001	>A> 7906519	Feb 17, 2029	U-1116			
	>A> 7915269	Feb 17, 2029	U-1007			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DESIRUDIN RECOMBINANT - IPRIVASK</u>						
N021271 001	6103515	Aug 15, 2017	DS			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	7884095	Feb 24, 2029	U-1111			
	7884095*PED	Aug 24, 2029				
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	>A> 6133251	Oct 25, 2016	DP U-828	Y		
	>A> 6133251	Oct 25, 2016	DP U-112	Y		
	>A> 6133251	Oct 25, 2016	DP U-1	Y		
	>A> 6884793	Oct 25, 2016	DP	Y		
<u>DORIPENEM - DORIBAX</u>						
N022106 001	5317016	Jun 05, 2015	DS DP U-282			
<u>DORIPENEM - DORIBAX</u>						
N022106 002	5317016	Jun 05, 2015	DS DP U-282			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 001	>A> 7915307	Aug 24, 2027	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 002	>A> 7915307	Aug 24, 2027	U-620			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N022574 001	5798338	Jul 10, 2015	DP			
	6441168	Apr 17, 2020	DS			
	6958326	Dec 20, 2021	DP			
	7163931	Mar 03, 2022	U-1			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 001	5714504	Feb 03, 2015	DP U-1053			
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS U-1053			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1053			
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS U-1053			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 002	5714504	Feb 03, 2015	DP U-1053			
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS U-1053			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1053			
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS U-1053			
	7411070*PED	Nov 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE</u>						
N022262 001	>A> 7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N021840 001	>A> 7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N022573 001	5552394	Jul 22, 2014	U-828			
	6667050	Apr 06, 2019	DP U-828			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 001	7887845	Mar 25, 2019	DP			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 002	6878717	Nov 05, 2019	U-1016		NCE	Jan 18, 2013
	7037917	Nov 05, 2019	DS DP U-1016			
	7887845	Mar 25, 2019	DP			
<u>EVEROLIMUS - AFINITOR</u>						
N022334 001					>A> ODE	Oct 29, 2017
<u>EVEROLIMUS - AFINITOR</u>						
N022334 002					>A> ODE	Oct 29, 2017
<u>EVEROLIMUS - AFINITOR</u>						
N022334 003					>A> NCE >A> ODE	Mar 30, 2014 Oct 29, 2017
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 001	5424286	Dec 01, 2016	U-653			
	5424286	Dec 01, 2016	U-1108			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 002	5424286	Dec 01, 2016	U-653			
	5424286	Dec 01, 2016	U-1108			
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 001					M-98	Jan 31, 2014
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 002					M-98	Jan 31, 2014
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 003					M-98	Jan 31, 2014
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N021695 001	7863331	Aug 08, 2020	U-1107			
	7863331	Aug 08, 2020	U-1106			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N021695 003	7863331	Aug 08, 2020	U-1107			
	7863331	Aug 08, 2020	U-1106			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418 001	>A> 7915247	Aug 20, 2027	U-1061			
	>A> 7915247	Aug 20, 2027	U-1059			
	>A> 7915247	Aug 20, 2027	U-1000			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418 002	>A> 7915247	Aug 20, 2027	U-1061			
	>A> 7915247	Aug 20, 2027	U-1059			
	>A> 7915247	Aug 20, 2027	U-1000			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 001	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	>A> 7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 002	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	>A> 7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 003	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	>A> 7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 004	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	>A> 7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 005	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	>A> 7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 006	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	>A> 7910132	Sep 24, 2019	DP U-767			
<u>FERUMOXYTOL - FERAHEME</u>						
N022180 001	7871597	Mar 08, 2020	DS DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	7855230	May 11, 2019	U-913			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	7855230	May 11, 2019	U-913			
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE</u>						
A079043 001					PC	Jul 27, 2011
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N021112 001	>A> 7915243	Mar 22, 2026	DP			
<u>FULVESTRANT - FASLODEX</u>						
N021344 001	6774122	Jan 09, 2021	U-596		D-126	Sep 09, 2013
	6774122*PED	Jul 09, 2021			PED	Mar 09, 2014
	7456160	Jan 09, 2021	U-596			
	7456160*PED	Jul 09, 2021				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN - GABAPENTIN</u>						
A078974	001				PC	Aug 22, 2011
<u>GABAPENTIN - GRALISE</u>						
N022544	001	>A> 6340475	Sep 19, 2016	DP	NP	Jan 28, 2014
		>A> 6488962	Jun 20, 2020	DP		
		>A> 6635280	Sep 19, 2016	DP		
		>A> 6723340	Oct 25, 2021	DP		
		>A> 7438927	Feb 26, 2024	U-1114		
		>A> 7731989	Oct 25, 2022	DP		
<u>GABAPENTIN - GRALISE</u>						
N022544	002	>A> 6340475	Sep 19, 2016	DP	NP	Jan 28, 2014
		>A> 6488962	Jun 20, 2020	DP		
		>A> 6635280	Sep 19, 2016	DP		
		>A> 6723340	Oct 25, 2021	DP		
		>A> 7438927	Feb 26, 2024	U-1114		
		>A> 7731989	Oct 25, 2022	DP		
<u>GADOBUTROL - GADAVIST</u>						
N201277	001	>A> 5980864	Nov 09, 2016	DS DP U-1119	>A> NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277	002	>A> 5980864	Nov 09, 2016	DS DP U-1119	>A> NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277	003	>A> 5980864	Nov 09, 2016	DS DP U-1119	>A> NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277	004	>A> 5980864	Nov 09, 2016	DS DP U-1119	>A> NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277	005	>A> 5980864	Nov 09, 2016	DS DP U-1119	>A> NCE	Mar 14, 2016
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711	001	>A> 5362475	Nov 08, 2011	DS		
		>A> 6676929	May 26, 2015	DP		
		>A> 7011815	Feb 01, 2015	U-1112		
		>A> 7060250	May 26, 2015	DS		
		>A> 7229606	May 26, 2015	U-1112		
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711	002	>A> 5362475	Nov 08, 2011	DS		
		>A> 6676929	May 26, 2015	DP		
		>A> 7011815	Feb 01, 2015	U-1112		
		>A> 7060250	May 26, 2015	DS		
		>A> 7229606	May 26, 2015	U-1112		
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE</u>						
A079183	001				PC	May 14, 2011
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A077983	001				PC	Jul 24, 2011
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A077983	002				PC	Jul 24, 2011
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037	001				I-635	Feb 25, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 002					I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 003					I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 004					I-635	Feb 25, 2014
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA</u>						
N021945 001					ODE	Feb 03, 2018
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 001					>A> I-636	Mar 24, 2014
<u>INSULIN RECOMBINANT HUMAN - HUMULIN R</u>						
N018780 001					>A> NR	Mar 25, 2014
<u>INSULIN RECOMBINANT HUMAN - HUMULIN R PEN</u>						
N018780 005					>A> NR	Mar 25, 2014
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454 001					NCE	Jan 14, 2016
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	>A> 6670384	Jan 23, 2022	DP U-960		>A> NCE	Oct 16, 2012
	>A> 6670384	Jan 23, 2022	DP U-959		>A> PED	Apr 16, 2013
	>A> 6670384*PED	Jul 23, 2022				
	>A> 7022330	Jan 23, 2022	DP U-958			
	>A> 7022330*PED	Jul 23, 2022				
	>A> 7125899	May 26, 2018	DS DP U-957			
	>A> 7125899*PED	Nov 26, 2018				
	>A> 7312237	Aug 21, 2024	U-965			
	>A> 7312237*PED	Feb 21, 2025				
	>A> RE41393	Feb 08, 2022	U-961			
	>A> RE41393*PED	Aug 08, 2022				
	>A> RE41911	May 26, 2018	DS DP U-961			
	>A> RE41911*PED	Nov 26, 2018				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	>A> 6670384	Jan 23, 2022	DP U-960		>A> NCE	Oct 16, 2012
	>A> 6670384	Jan 23, 2022	DP U-959		>A> PED	Apr 16, 2013
	>A> 6670384*PED	Jul 23, 2022				
	>A> 7022330	Jan 23, 2022	DP U-958			
	>A> 7022330*PED	Jul 23, 2022				
	>A> 7125899	May 26, 2018	DS DP U-957			
	>A> 7125899*PED	Nov 26, 2018				
	>A> 7312237	Aug 21, 2024	U-965			
	>A> 7312237*PED	Feb 21, 2025				
	>A> RE41393	Feb 08, 2022	U-961			
	>A> RE41393*PED	Aug 08, 2022				
	>A> RE41911	May 26, 2018	DS DP U-961			
	>A> RE41911*PED	Nov 26, 2018				
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 001	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 002	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 003	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 001	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 002	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	7855217	Nov 24, 2024	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	7855217	Nov 24, 2024	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	7855217	Nov 24, 2024	DS DP			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 001	>A> 7919116	Mar 20, 2018	DP			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 002	>A> 7919116	Mar 20, 2018	DP			
<u>METRONIDAZOLE - VANDAZOLE</u>						
N021806 001	7456207	Sep 22, 2024	DP			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 001	7888342	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 002	7888342	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 003	7888342	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 004	7888342	Nov 05, 2021	U-882			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 001	>A> 7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 002	>A> 7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 003	>A> 7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 004	>A> 7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 005	>A> 7919483	Feb 28, 2027	U-1078			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 006	>A> 7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 007	>A> 7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 008	>A> 7919483	Feb 28, 2027	U-1078			
<u>MOMETASONE FUROATE MONOHYDRATE - NASONEX</u>						
N020762 001					M-99	Jan 19, 2014
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N201152 001	>A> 5366972	Nov 22, 2011	DS DP U-167		>A> NDF	Mar 25, 2014
	>A> 5366972*PED	May 22, 2012				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 001	>A> 5952375	Feb 27, 2015	DS DP			
	>A> 5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 002	>A> 5952375	Feb 27, 2015	DS DP			
	>A> 5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 003	>A> 5952375	Feb 27, 2015	DS DP			
	>A> 5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246 001	>A> 5763483	Dec 27, 2016	DS U-376			
	>A> 5763483	Dec 27, 2016	DS U-1113			
	>A> 5952375	Feb 27, 2015	DS DP			
	>A> 5952375*PED	Aug 27, 2015				
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	>A> RE41884	Aug 14, 2016	U-1117			
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 001					>A> M-61 >A> PED	Mar 17, 2014 Sep 17, 2014
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 002					>A> M-61 >A> PED	Mar 17, 2014 Sep 17, 2014
<u>PERFLUTREN - DEFINITY</u>						
N021064 001	>A> 5527521	Feb 22, 2015	DP U-665			
	5585112	Dec 17, 2013	DP			
<u>PLERIXAFOR - MOZOBIL</u>						
N022311 001	>A> 7897590	Jul 22, 2023	U-936			
	RE42152	Dec 10, 2013	DP			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145 001	7169780	Oct 03, 2023	DS DP			
<u>RANOLAZINE - RANEXA</u>						
N021526 001	>A> 6369062	May 27, 2019	DP	Y		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RETAPAMULIN - ALTABAX</u>						
N022055 001	7875630	Feb 14, 2027	DS			
	RE39128	Apr 12, 2021	DS DP U-805			
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	>A> 7902206	Jun 19, 2024	DS DP			
	>A> 7906542	Jun 01, 2025	DS DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	>A> 7612199	Jun 19, 2024	DS DP			
	>A> 7902206	Jun 19, 2024	DS DP			
	>A> 7906542	Jun 01, 2025	DS DP			
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 001	>A> 5602162	Feb 11, 2014		Y		
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 002	>A> 5602162	Feb 11, 2014		Y		
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 001	>A> 5602162	Feb 11, 2014	U-240	Y		
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 002	>A> 5602162	Feb 11, 2014	U-240	Y		
<u>ROFLUMILAST - DALIRESP</u>						
N022522 001	>A> 5712298	Jan 27, 2015	DS DP U-1115		NCE	Feb 28, 2016
<u>RUFINAMIDE - BANZEL</u>						
N201367 001	>A> 6740669	Aug 17, 2020	DS DP		>A> NCE >A> ODE	Nov 14, 2013 Nov 14, 2015
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N201444 001					ODE	Jan 14, 2018
<u>SODIUM OXYBATE - XYREM</u>						
N021196 001	7668730	Jun 16, 2024	U-1110			
	7895059	Dec 17, 2022	U-1110			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N021923 001	>A> 7897623	Jan 12, 2020	DP			
<u>SPINOSAD - NATROBA</u>						
N022408 001	5496931	Mar 05, 2013	DS U-1105		NCE	Jan 18, 2016
	6063771	Jun 22, 2019	DP U-1105			
	6342482	Jun 22, 2019	DP U-1105			
	7030095	Jul 02, 2021	DP U-1105			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	7776007	Apr 09, 2025	DP			
	>A> 7901385	Jul 31, 2026	DP			
<u>TELBIVUDINE - TYZEKA</u>						
N022011 001	7858594	Sep 11, 2023	DS DP U-999			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
<u>TIGECYCLINE - TYGACIL</u>						
N021821 001	7879828	Feb 05, 2029	DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 001	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 002	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 003	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A078148 001					PC	Jun 04, 2011

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
3. **** The expiration date for U.S. Patent No. 5,608,075 is March 4, 2009.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>